Zofia Czaplińska-Paszek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zofia Czaplińska-Paszek has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anna Maria Zakrzewska
Central Clinical Hospital of the Medical University of Łódź, Łódź, Poland
5 shared publications - Aleksander Midera
Independent Public Healthcare Center, Brzeziny, Poland
4 shared publications - Julia Agnieszka Michalak
Independent Public Healthcare Center, Kościan, Poland
4 shared publications - Julia Aleksandra Leśniak
Central Clinical Hospital of the Medical University of Łódź, Pomorska 251, 92-213 Łódź, Poland
4 shared publications - Kinga Popielarska
Medical University of Gdansk, Gdansk, Poland
4 shared publications - Klaudia Elżbieta Niwińska
Independent Public Clinical Hospital named after Prof. W. Orłowski (CMKP), Warszawa, Poland
4 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
SUDDEN CARDIAC ARREST DURING MASS RUNNING EVENTS IN THE CONTEXT OF THE 2025 EUROPEAN RESUSCITATION COUNCIL GUIDLINES AND CURRENT SCIENTIFIC EVIDENCE
Introduction and objective: Sudden cardiac arrest (SCA) during outdoor sport training is a complication where a quick response from medical professionals is crucial for increasing chances of survival. In parallel with the global growth in running events, there is a need to implement new recommendations and technologies to improve prevention, detection, and treatment of SCA among runners. Review Methods: A comprehensive literature review was conducted, analyzing studies indexed in PubMed, Google Scholar, and the official ERC Guidelines from 2021 and 2025. Key findings: Recent data suggest that, although the number of SCA cases in mass running events has remained relatively stable over the past decade, running-related deaths have declined. These outcomes are likely attributable to significant improvements in emergency action planning, widespread AED availability, and enhanced first-aid education. There are also new ideas that can further improve those outcomes, not only in treatment but also in SCA prophylaxis. New preventive and diagnostic strategies, such as point-of-care blood gas analysis (POC BGA) and risk-profiling patient triage, focus primarily on early triage and smartwatch pulse-detector systems, offering a new perspective on more rapid detection of SCA during outdoor activity. Advances in treatment focus on optimizing the prehospital chain of survival through mobile AED teams, GPS-enabled responder coordination, and structured “field-of-play” protocols. Further research is needed to reduce the time to defibrillation and improve neurological outcomes during endurance events.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessSUDDEN CARDIAC ARREST DURING MASS RUNNING EVENTS IN THE CONTEXT OF THE 2025 EUROPEAN RESUSCITATION COUNCIL GUIDLINES AND CURRENT SCIENTIFIC EVIDENCE
Introduction and objective: Sudden cardiac arrest (SCA) during outdoor sport training is a complication where a quick response from medical professionals is crucial for increasing chances of survival. In parallel with the global growth in running events, there is a need to implement new recommendations and technologies to improve prevention, detection, and treatment of SCA among runners. Review Methods: A comprehensive literature review was conducted, analyzing studies indexed in PubMed, Google Scholar, and the official ERC Guidelines from 2021 and 2025. Key findings: Recent data suggest that, although the number of SCA cases in mass running events has remained relatively stable over the past decade, running-related deaths have declined. These outcomes are likely attributable to significant improvements in emergency action planning, widespread AED availability, and enhanced first-aid education. There are also new ideas that can further improve those outcomes, not only in treatment but also in SCA prophylaxis. New preventive and diagnostic strategies, such as point-of-care blood gas analysis (POC BGA) and risk-profiling patient triage, focus primarily on early triage and smartwatch pulse-detector systems, offering a new perspective on more rapid detection of SCA during outdoor activity. Advances in treatment focus on optimizing the prehospital chain of survival through mobile AED teams, GPS-enabled responder coordination, and structured “field-of-play” protocols. Further research is needed to reduce the time to defibrillation and improve neurological outcomes during endurance events.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
DIAGNOSIS AND TREATMENT OF ACUTE ADRENAL CRISIS IN THE SETTING OF THE EMERGENCY DEPARTMENT - A LITERATURE REVIEW
Introduction and objective: Acute adrenal crisis (AAC) is a life-threatening condition, often under-recognized due to its rarity. Over the years, technological advances have occurred across many branches of medicine, including new solutions for diagnosing and treating AAC. However, they remain fragmented across the literature. In this review, we sought to systematically evaluate and summarize contemporary innovations that may help emergency medicine practitioners to be more confident in their diagnoses and, therefore, make more confident under-pressure clinical decisions. Review Methods: We searched the PubMed and Google Scholar databases, focusing on papers published between 2020 and 2025. Brief description of knowledge: Currently, AAC is treated empirically with hydrocortisone. Quick tests for cortisol levels are not widely available; diagnosis is based mainly on clinical symptoms and electrolyte disturbances. Summary: Developments in diagnostic approaches, such as saliva-based, aptamer-based point-of-care cortisol assays, may aid differential diagnosis of AAC in emergency departments (EDs) and reduce time to hydrocortisone administration.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessDIAGNOSIS AND TREATMENT OF ACUTE ADRENAL CRISIS IN THE SETTING OF THE EMERGENCY DEPARTMENT - A LITERATURE REVIEW
Introduction and objective: Acute adrenal crisis (AAC) is a life-threatening condition, often under-recognized due to its rarity. Over the years, technological advances have occurred across many branches of medicine, including new solutions for diagnosing and treating AAC. However, they remain fragmented across the literature. In this review, we sought to systematically evaluate and summarize contemporary innovations that may help emergency medicine practitioners to be more confident in their diagnoses and, therefore, make more confident under-pressure clinical decisions. Review Methods: We searched the PubMed and Google Scholar databases, focusing on papers published between 2020 and 2025. Brief description of knowledge: Currently, AAC is treated empirically with hydrocortisone. Quick tests for cortisol levels are not widely available; diagnosis is based mainly on clinical symptoms and electrolyte disturbances. Summary: Developments in diagnostic approaches, such as saliva-based, aptamer-based point-of-care cortisol assays, may aid differential diagnosis of AAC in emergency departments (EDs) and reduce time to hydrocortisone administration.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
MALIGNANCY AND ATRIAL FIBRILLATION – HARDSHIPS TO MANAGE BLEEDING AND THROMBOEMBOLIC RISK
Atrial fibrillation (AF) and cancer are conditions that often coexist. Both of them, as well as their treatment, are connected with changes in coagulation processes, increasing the risk of bleeding or thromboembolic events. Despite that, the level of evidence supporting existing recommendations remains low. (Lyon et al., 2022) In this study, we focused on analyzing the existing literature on the assessment and management of bleeding and thromboembolic risk, with the aim of establishing an evidence-based approach to managing bleeding and thromboembolic risk in oncology patients with AF. Cancer is widely associated with a hypercoagulability state, but in the case of AF and stroke risk, it does not seem to be higher in general in comparison with non-cancer populations. It changes when individual cancer types are analyzed. As for the bleeding risk, many malignancies seem to increase it. Another challenge is that the existing risk scores often show lower predictive value for patients with recent malignancy. There is a need for individual assessment in every patient, but we lack the tools to make it easier for clinicians. Cardio-oncology guidelines addressing AF do exist, but the level of evidence supporting them remains low; thus, further research in this field is needed.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessMALIGNANCY AND ATRIAL FIBRILLATION – HARDSHIPS TO MANAGE BLEEDING AND THROMBOEMBOLIC RISK
Atrial fibrillation (AF) and cancer are conditions that often coexist. Both of them, as well as their treatment, are connected with changes in coagulation processes, increasing the risk of bleeding or thromboembolic events. Despite that, the level of evidence supporting existing recommendations remains low. (Lyon et al., 2022) In this study, we focused on analyzing the existing literature on the assessment and management of bleeding and thromboembolic risk, with the aim of establishing an evidence-based approach to managing bleeding and thromboembolic risk in oncology patients with AF. Cancer is widely associated with a hypercoagulability state, but in the case of AF and stroke risk, it does not seem to be higher in general in comparison with non-cancer populations. It changes when individual cancer types are analyzed. As for the bleeding risk, many malignancies seem to increase it. Another challenge is that the existing risk scores often show lower predictive value for patients with recent malignancy. There is a need for individual assessment in every patient, but we lack the tools to make it easier for clinicians. Cardio-oncology guidelines addressing AF do exist, but the level of evidence supporting them remains low; thus, further research in this field is needed.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
REVIEW OF THE NEW AVALANCHE RESCUE PROCEDURES ACCORDING TO THE NEW ERC 2025 GUIDELINES
Introduction and objective: Emergency medicine is nowadays a highly specialised branch of medicine. Regular updates on rescue procedures lead to the compilation of highly specialised guidelines. The rise in mobility among people encourages travel and participation in sports. Winter sports such as skiing and snowboarding increase the average time spent in mountain regions, thereby increasing the risk of avalanche exposure. To ensure high-quality avalanche rescue, official guidelines must be published and regularly revisited. Review Methods: A comprehensive literature review was conducted, analyzing studies indexed in PubMed and the official ERC Guidelines from 2021 and 2025. Brief description of the state of knowledge: The first official avalanche rescue guidelines were published in 2021 by the European Resuscitation Council. Since then, studies have examined their efficacy and sought better solutions. In 2022, a group of experts published an algorithm—Avalife—that outlined systematic, step-by-step Basic Life Support (BLS) recommendations in case of a shortage of rescuers at the site of an accident. The latest ERC Guidelines, published in 2025, introduce a new avalanche-rescue algorithm and incorporate the Avalife algorithm into official procedures, thereby establishing a cohesive avalanche-rescue policy. Summary: In this review, we analyse the existing literature, with particular emphasis on the new ERC 2025 Guidelines, to present the current state of knowledge on this issue.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessREVIEW OF THE NEW AVALANCHE RESCUE PROCEDURES ACCORDING TO THE NEW ERC 2025 GUIDELINES
Introduction and objective: Emergency medicine is nowadays a highly specialised branch of medicine. Regular updates on rescue procedures lead to the compilation of highly specialised guidelines. The rise in mobility among people encourages travel and participation in sports. Winter sports such as skiing and snowboarding increase the average time spent in mountain regions, thereby increasing the risk of avalanche exposure. To ensure high-quality avalanche rescue, official guidelines must be published and regularly revisited. Review Methods: A comprehensive literature review was conducted, analyzing studies indexed in PubMed and the official ERC Guidelines from 2021 and 2025. Brief description of the state of knowledge: The first official avalanche rescue guidelines were published in 2021 by the European Resuscitation Council. Since then, studies have examined their efficacy and sought better solutions. In 2022, a group of experts published an algorithm—Avalife—that outlined systematic, step-by-step Basic Life Support (BLS) recommendations in case of a shortage of rescuers at the site of an accident. The latest ERC Guidelines, published in 2025, introduce a new avalanche-rescue algorithm and incorporate the Avalife algorithm into official procedures, thereby establishing a cohesive avalanche-rescue policy. Summary: In this review, we analyse the existing literature, with particular emphasis on the new ERC 2025 Guidelines, to present the current state of knowledge on this issue.
- Open Access
- 3 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
GLP-1 Analogues in Rheumatology - The Influence of Obesity on the Effectiveness of Biological Treatment
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.
- 3 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessGLP-1 Analogues in Rheumatology - The Influence of Obesity on the Effectiveness of Biological Treatment
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Proton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessProton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Proton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessProton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- Open Access
- 1 January 2026
- Published by CNBOP-PIB Centrum Naukowo-Badawcze Ochrony Przeciwpozarowej in Safety and Fire Technology
- Vol. 67 (1) , 210-222
Using the Kendrick Extrication Device in the National Rescue and Firefighting System
Purpose: The aim of this study was to assess the frequency of Kendrick extrication device (KED) use among rescuers and to analyse the current scientific evidence regarding its effectiveness and safety. The study was motivated by differences observed in recent years in the qualified first aid training programmes for State Fire Service (PSP) and Volunteer Fire Service (OSP) firefighters with regard to the use of this device Project and methods: The study was conducted between July 2022 and March 2026 among 210 firefighters, using a diagnostic survey with an original questionnaire distributed via Google Forms. The survey was addressed to firefighters serving in both professional and volunteer fire protection units. The questionnaire was disseminated through social media platforms and professional groups bringing together individuals involved in fire protection services. Responses concerning the frequency of Kendrick Extrication Device use, equipment availability, and subjective assessment of its usefulness in rescue operations were analysed. In addition, a review of the current scientific literature on the effectiveness, safety, and potential complications of the Kendrick extrication device in prehospital medicine was conducted using publications available in PubMed, Scopus, and Google Scholar. Results: More than half of the surveyed rescuers reported not having used the Kendrick Extrication Device in practice while providing qualified first aid. A substantial proportion of respondents also indicated that this device was not available in the equipment of their rescue units. The most frequently reported reason for the device's limited use was the time required to apply it properly during patient extrication. Analysis of the available literature suggests that the use of spinal immobilisation devices in selected situations may be associated with a risk of complications and prolonged patient extrication time. Conclusions: The study findings indicate limited use of the Kendrick extrication device in rescue practice and low availability of this equipment in State Fire Service units. Respondents identified the time-consuming nature of device application during patient extrication as the main reason for abandoning its use. Current scientific evidence suggests that rapid patient extrication without this type of equipment may be a safe alternative in selected clinical situations. The results obtained may support the rationale for limiting the use of the Kendrick Extrication Device and highlight the need for further research into more intuitive and effective methods for patient extrication and stabilization.
- 1 January 2026
- Published by CNBOP-PIB Centrum Naukowo-Badawcze Ochrony Przeciwpozarowej in Safety and Fire Technology
- Vol. 67 (1) , 210-222
Open AccessUsing the Kendrick Extrication Device in the National Rescue and Firefighting System
Purpose: The aim of this study was to assess the frequency of Kendrick extrication device (KED) use among rescuers and to analyse the current scientific evidence regarding its effectiveness and safety. The study was motivated by differences observed in recent years in the qualified first aid training programmes for State Fire Service (PSP) and Volunteer Fire Service (OSP) firefighters with regard to the use of this device Project and methods: The study was conducted between July 2022 and March 2026 among 210 firefighters, using a diagnostic survey with an original questionnaire distributed via Google Forms. The survey was addressed to firefighters serving in both professional and volunteer fire protection units. The questionnaire was disseminated through social media platforms and professional groups bringing together individuals involved in fire protection services. Responses concerning the frequency of Kendrick Extrication Device use, equipment availability, and subjective assessment of its usefulness in rescue operations were analysed. In addition, a review of the current scientific literature on the effectiveness, safety, and potential complications of the Kendrick extrication device in prehospital medicine was conducted using publications available in PubMed, Scopus, and Google Scholar. Results: More than half of the surveyed rescuers reported not having used the Kendrick Extrication Device in practice while providing qualified first aid. A substantial proportion of respondents also indicated that this device was not available in the equipment of their rescue units. The most frequently reported reason for the device's limited use was the time required to apply it properly during patient extrication. Analysis of the available literature suggests that the use of spinal immobilisation devices in selected situations may be associated with a risk of complications and prolonged patient extrication time. Conclusions: The study findings indicate limited use of the Kendrick extrication device in rescue practice and low availability of this equipment in State Fire Service units. Respondents identified the time-consuming nature of device application during patient extrication as the main reason for abandoning its use. Current scientific evidence suggests that rapid patient extrication without this type of equipment may be a safe alternative in selected clinical situations. The results obtained may support the rationale for limiting the use of the Kendrick Extrication Device and highlight the need for further research into more intuitive and effective methods for patient extrication and stabilization.
- Open Access
- 30 December 2025
- Published by Wojskowy Instytut Medyczny – Panstwowy Instytut Badawczy in Lekarz Wojskowy
- Vol. 103 (4) , 301-305
Assessment of preparedness of intern physicians in Mazowieckie Voivodeship for civil-military cooperation in the event of a potential armed conflict
Wprowadzenie i cel: Obecna sytuacja geopolityczna oraz trwające konflikty zbrojne o zasięgu międzynarodowym skłaniają do refleksji na temat poziomu przygotowania kadr medycznych na wypadek konieczności ich udziału w realnym konflikcie zbrojnym. Z tego powodu autorzy postanowili poddać ocenie kompetencje lekarzy stażystów, a więc osób rozpoczynających karierę zawodową, realizujących aktualny program nauczania. Materiał i metody: Opracowano autorski formularz składający się z 10 zamkniętych pytań jednokrotnego wyboru, mający ocenić znajomość procedur opracowanych przez Komitet Tactical Combat Casualty Care (TCCC). Wyniki: Średni wynik uzyskany przez lekarzy stażystów wyniósł niespełna 30% poprawnych odpowiedzi. Dodatkowo udało się ustalić obszary, które stanowią największą trudność dla respondentów, takie jak antybiotykoterapia czy tamowanie krwotoków. Wnioski: Uzyskane wyniki wskazują na potrzebę rozważenia rozszerzenia programu nauczania na kierunku lekarskim o treści obejmujące zagadnienia z zakresu TCCC, a także wykorzystania zagranicznych doświadczeń w celu rozwijania współpracy szkoleniowej o zasięgu międzynarodowym.
- 30 December 2025
- Published by Wojskowy Instytut Medyczny – Panstwowy Instytut Badawczy in Lekarz Wojskowy
- Vol. 103 (4) , 301-305
Open AccessAssessment of preparedness of intern physicians in Mazowieckie Voivodeship for civil-military cooperation in the event of a potential armed conflict
Wprowadzenie i cel: Obecna sytuacja geopolityczna oraz trwające konflikty zbrojne o zasięgu międzynarodowym skłaniają do refleksji na temat poziomu przygotowania kadr medycznych na wypadek konieczności ich udziału w realnym konflikcie zbrojnym. Z tego powodu autorzy postanowili poddać ocenie kompetencje lekarzy stażystów, a więc osób rozpoczynających karierę zawodową, realizujących aktualny program nauczania. Materiał i metody: Opracowano autorski formularz składający się z 10 zamkniętych pytań jednokrotnego wyboru, mający ocenić znajomość procedur opracowanych przez Komitet Tactical Combat Casualty Care (TCCC). Wyniki: Średni wynik uzyskany przez lekarzy stażystów wyniósł niespełna 30% poprawnych odpowiedzi. Dodatkowo udało się ustalić obszary, które stanowią największą trudność dla respondentów, takie jak antybiotykoterapia czy tamowanie krwotoków. Wnioski: Uzyskane wyniki wskazują na potrzebę rozważenia rozszerzenia programu nauczania na kierunku lekarskim o treści obejmujące zagadnienia z zakresu TCCC, a także wykorzystania zagranicznych doświadczeń w celu rozwijania współpracy szkoleniowej o zasięgu międzynarodowym.
- Open Access
- 28 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Zuranolone in Postpartum Depression: A Review of the First Oral Neurosteroid Treatment
Background: Postpartum depression (PPD) is a severe mood disorder affecting 1 in 7 postpartum women. It significantly impacts maternal functioning and infant development. SSRIs are currently the first-line treatment, but require 4-8 weeks to take effect and show variable efficacy. The neurosteroid hypothesis connects PPD symptoms to an abrupt drop in allopregnanolone after childbirth. Zuranolone, a synthetic modulator of the GABA-A receptor, is the first oral neurosteroid specifically indicated for postpartum depression. Aim: This review analyzes zuranolone’s pharmacology, Phase III clinical efficacy, and its practical use for postpartum depression. Material and methods: We conducted a comprehensive literature review using PubMed. Search terms included „zuranolone", „neurosteroid", and "postpartum depression”. We reviewed publications from 2015 to 2025, focusing on Phase III clinical studies, pharmacological analyses, and FDA/EMA regulatory documents. Results: Zuranolone is administered as 50 mg once daily for 14 days. Two Phase III randomized, placebo-controlled trials (n=150, n=196) evaluated zuranolone for moderate to severe postpartum depression. In the pivotal trial, the least-squares mean difference on the HAM-D was -4.0 versus placebo (95% CI: -6.3 to -1.7; p=0.001). Response rates were 57.0% versus 38.9% (p=0.021), and remission rates were 26.9% versus 16.7%. Effects were seen by day 3 and lasted through day 45. Conclusions: Zuranolone represents a significant therapeutic advance in the treatment of postpartum depression. It offers immediate symptom relief during the critical early postpartum period. Further research is needed to assess effectiveness and safety in a more heterogeneous population, as well as the long-term effects in mood disorders.
- 28 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Open AccessZuranolone in Postpartum Depression: A Review of the First Oral Neurosteroid Treatment
Background: Postpartum depression (PPD) is a severe mood disorder affecting 1 in 7 postpartum women. It significantly impacts maternal functioning and infant development. SSRIs are currently the first-line treatment, but require 4-8 weeks to take effect and show variable efficacy. The neurosteroid hypothesis connects PPD symptoms to an abrupt drop in allopregnanolone after childbirth. Zuranolone, a synthetic modulator of the GABA-A receptor, is the first oral neurosteroid specifically indicated for postpartum depression. Aim: This review analyzes zuranolone’s pharmacology, Phase III clinical efficacy, and its practical use for postpartum depression. Material and methods: We conducted a comprehensive literature review using PubMed. Search terms included „zuranolone", „neurosteroid", and "postpartum depression”. We reviewed publications from 2015 to 2025, focusing on Phase III clinical studies, pharmacological analyses, and FDA/EMA regulatory documents. Results: Zuranolone is administered as 50 mg once daily for 14 days. Two Phase III randomized, placebo-controlled trials (n=150, n=196) evaluated zuranolone for moderate to severe postpartum depression. In the pivotal trial, the least-squares mean difference on the HAM-D was -4.0 versus placebo (95% CI: -6.3 to -1.7; p=0.001). Response rates were 57.0% versus 38.9% (p=0.021), and remission rates were 26.9% versus 16.7%. Effects were seen by day 3 and lasted through day 45. Conclusions: Zuranolone represents a significant therapeutic advance in the treatment of postpartum depression. It offers immediate symptom relief during the critical early postpartum period. Further research is needed to assess effectiveness and safety in a more heterogeneous population, as well as the long-term effects in mood disorders.